However, they are not the only factors that contribute to the onset and development of AD, given the fact that current treatments and clinical trials for AD targeting the synthesis and clearance of Aβ and p-tau failed (Zlokovic, 2005; Murphy and LeVine, 2010; Wang et al., 2016; Fang et al., 2022b). The gene discussed is MAPT; the disease is Alzheimer disease.